Funder
U.S. Department of Health & Human Services | National Institutes of Health
Funders listed above apply for the entire manuscript
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference87 articles.
1. Network NCC. NCCN Guidelines Version 3.2019: Myeloproliferative neoplasms. 2019 [cited 2019 10/11/2019]; https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf.
2. Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017;130:2475–83.
3. Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3023 mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599–610.
4. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.
5. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献